151 related articles for article (PubMed ID: 20581581)
1. Treatment of pulmonary epithelioid hemangioendothelioma with bevacizumab.
Kim YH; Mishima M; Miyagawa-Hayashino A
J Thorac Oncol; 2010 Jul; 5(7):1107-8. PubMed ID: 20581581
[No Abstract] [Full Text] [Related]
2. Bevacizumab chemotherapy for pulmonary epithelioid hemangioendothelioma with severe dyspnea.
Mizota A; Shitara K; Fukui T
J Thorac Oncol; 2011 Mar; 6(3):651-2. PubMed ID: 21317750
[No Abstract] [Full Text] [Related]
3. Pulmonary epithelioid haemangioendothelioma and bevacizumab.
Belmont L; Zemoura L; Couderc LJ
J Thorac Oncol; 2008 May; 3(5):557-8. PubMed ID: 18449015
[No Abstract] [Full Text] [Related]
4. Bevacizumab for recurrent hemangioendothelioma.
Trautmann K; Bethke A; Ehninger G; Folprecht G
Acta Oncol; 2011 Jan; 50(1):153-4. PubMed ID: 20950228
[No Abstract] [Full Text] [Related]
5. Pazopanib for metastatic pulmonary epithelioid hemangioendothelioma-a suitable treatment option: case report and review of anti-angiogenic treatment options.
Semenisty V; Naroditsky I; Keidar Z; Bar-Sela G
BMC Cancer; 2015 May; 15():402. PubMed ID: 25967676
[TBL] [Abstract][Full Text] [Related]
6. Complete regression of a non-small cell lung cancer choroidal metastasis with intravitreal bevacizumab.
D'Antonio C; Viterbo A; Romiti A; Enrici MM; Lauro S; Marchetti P
J Thorac Oncol; 2012 Feb; 7(2):468-9. PubMed ID: 22252564
[No Abstract] [Full Text] [Related]
7. Vascular-endothelial-growth-factor (VEGF) expression and possible response to angiogenesis inhibitor bevacizumab in metastatic alveolar soft part sarcoma.
Azizi AA; Haberler C; Czech T; Gupper A; Prayer D; Breitschopf H; Acker T; Slavc I
Lancet Oncol; 2006 Jun; 7(6):521-3. PubMed ID: 16750504
[No Abstract] [Full Text] [Related]
8. Bevacizumab in advanced lung cancer: in search of the right drug for the right patient.
Burns TF; Juergens RA
Oncology (Williston Park); 2010 Nov; 24(13):1223-4, 1226. PubMed ID: 21192562
[No Abstract] [Full Text] [Related]
9. Thalidomide inhibits the growth and progression of hepatic epithelioid hemangioendothelioma.
Mascarenhas RC; Sanghvi AN; Friedlander L; Geyer SJ; Beasley HS; Van Thiel DH
Oncology; 2004; 67(5-6):471-5. PubMed ID: 15714004
[TBL] [Abstract][Full Text] [Related]
10. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
Grothey A; Ellis LM
Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab in adult malignant brainstem gliomas.
Raza S; Donach M
J Neurooncol; 2009 Nov; 95(2):299-300. PubMed ID: 19506812
[No Abstract] [Full Text] [Related]
12. Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab.
Laud K; Spaide RF; Freund KB; Slakter J; Klancnik JM
Retina; 2006 Oct; 26(8):960-3. PubMed ID: 17031300
[No Abstract] [Full Text] [Related]
13. More on bevacizumab in hereditary hemorrhagic telangiectasia.
Oosting S; Nagengast W; de Vries E
N Engl J Med; 2009 Aug; 361(9):931; author reply 931-2. PubMed ID: 19710496
[No Abstract] [Full Text] [Related]
14. Pulmonary epithelioid hemangioendothelioma.
Rosengarten D; Kramer MR; Amir G; Fuks L; Berkman N
Isr Med Assoc J; 2011 Nov; 13(11):676-9. PubMed ID: 22279701
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab in first-line treatment of metastatic breast cancer: a viewpoint by David Miles.
Miles D
Drugs; 2007; 67(12):1800-1. PubMed ID: 17683177
[No Abstract] [Full Text] [Related]
16. Intracameral bevacizumab effectively reduces aqueous vascular endothelial growth factor concentrations in neovascular glaucoma.
Grover S; Gupta S; Sharma R; Brar VS; Chalam KV
Br J Ophthalmol; 2009 Feb; 93(2):273-4. PubMed ID: 18617542
[No Abstract] [Full Text] [Related]
17. Multifocal epithelioid hemangioendothelioma: case report of a clinical chamaeleon.
Bölke E; Gripp S; Peiper M; Budach W; Schwarz A; Orth K; Reinecke P; van de Nes JA
Eur J Med Res; 2006 Nov; 11(11):462-6. PubMed ID: 17182357
[TBL] [Abstract][Full Text] [Related]
18. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.
Willett CG; Boucher Y; di Tomaso E; Duda DG; Munn LL; Tong RT; Chung DC; Sahani DV; Kalva SP; Kozin SV; Mino M; Cohen KS; Scadden DT; Hartford AC; Fischman AJ; Clark JW; Ryan DP; Zhu AX; Blaszkowsky LS; Chen HX; Shellito PC; Lauwers GY; Jain RK
Nat Med; 2004 Feb; 10(2):145-7. PubMed ID: 14745444
[TBL] [Abstract][Full Text] [Related]
19. More on bevacizumab in hereditary hemorrhagic telangiectasia.
Retornaz F; Rinaldi Y; Duvoux C
N Engl J Med; 2009 Aug; 361(9):931; author reply 931-2. PubMed ID: 19714790
[No Abstract] [Full Text] [Related]
20. Technology evaluation: bevacizumab, Genentech/Roche.
Salgaller ML
Curr Opin Mol Ther; 2003 Dec; 5(6):657-67. PubMed ID: 14755893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
